Literature DB >> 10403156

Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health.

L V Scott1, F Salahuddin, J Cooney, F Svec, T G Dinan.   

Abstract

BACKGROUND: Hyperactivity and hypoactivity of the HPA have been forwarded as of pathophysiological relevance in major depressive disorder and chronic fatigue syndrome (CFS), respectively.
METHODS: This study examines cortisol levels in the two disorders, and also assesses levels of the adrenal androgens, dehydroepiandrosterone (DHEA) and its sulphate derivative (DHEA-S), and 17-alpha-hydroxyprogesterone; 15 subjects with CFS diagnosed according to CDC criteria, 15 subjects with DSM III-R major depression and 11 healthy subjects were compared.
RESULTS: DHEA and DHEA-S levels were significantly lower in the CFS compared to the healthy group; DHEA-S levels, but not DHEA, were lower in the depressives; cortisol and 17-alpha-hydroxyprogesterone did not differ between the three groups.
CONCLUSIONS: A potential role for DHEA, both therapeutically and as a diagnostic tool, in CFS, is suggested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403156     DOI: 10.1016/s0165-0327(98)00169-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

Review 1.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  Cortisol and DHEA-S are associated with startle potentiation during aversive conditioning in humans.

Authors:  Christian Grillon; Daniel S Pine; Johanna M P Baas; Megan Lawley; Valerie Ellis; Dennis S Charney
Journal:  Psychopharmacology (Berl)       Date:  2005-07-29       Impact factor: 4.530

Review 3.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

Review 4.  Chronic fatigue syndrome: an update.

Authors:  R J Shephard
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

5.  Do dehydroepiandrosterone, progesterone, and testosterone influence women's depression and anxiety levels? Evidence from hair-based hormonal measures of 2105 rural Indian women.

Authors:  A Walther; C Tsao; R Pande; C Kirschbaum; E Field; L Berkman
Journal:  Psychoneuroendocrinology       Date:  2019-07-19       Impact factor: 4.905

6.  A systematic review of chronic fatigue syndrome: don't assume it's depression.

Authors:  James P Griffith; Fahd A Zarrouf
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 7.  Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

Authors:  Nicole Maninger; Owen M Wolkowitz; Victor I Reus; Elissa S Epel; Synthia H Mellon
Journal:  Front Neuroendocrinol       Date:  2008-12-03       Impact factor: 8.606

8.  Changes in fatigue, autonomic functions, and blood biomarkers due to sitting isometric yoga in patients with chronic fatigue syndrome.

Authors:  Takakazu Oka; Tokusei Tanahashi; Nobuyuki Sudo; Battuvshin Lkhagvasuren; Yu Yamada
Journal:  Biopsychosoc Med       Date:  2018-04-10

9.  The longitudinal effects of seated isometric yoga on blood biomarkers, autonomic functions, and psychological parameters of patients with chronic fatigue syndrome: a pilot study.

Authors:  Takakazu Oka; Tokusei Tanahashi; Battuvshin Lkhagvasuren; Yu Yamada
Journal:  Biopsychosoc Med       Date:  2019-11-05

10.  The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.

Authors:  Tayfun Turan; Hasan Basri Izgi; Saliha Ozsoy; Fatih Tanrıverdi; Mustafa Basturk; Akif Asdemir; Aslı Beşirli; Ertugrul Esel; Seher Sofuoglu
Journal:  Psychiatry Investig       Date:  2009-06-23       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.